1. HAYLEN B T, FREEMAN R M, SWIFT S E, COSSON M, DAVILA G W, DEPREST J, DWYER P L, FATTON B, KOCJANCIC E, LEE J. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J, 2010, 29(1): 4–20.
2. MCKELLAR K, BELLIN E, SCHOENBAUN E, ABRAHAM N. Prevalence, risk factors, and treatment for overactive bladder in a racially diverse population. Urology, 2019, 126: 70–75.
3. WEN J G, LI J S, WANG Z M, HUANG C X, SHANG X P, SU Z Q, LU Y T, SUO Z H, WANG Y, QIN G J. The prevalence and risk factors of OAB in middle-aged and old people in China. Neurourol Urodyn, 2014, 33(4): 387–391.
4. SHENG H F, ZHENG X Y, XIE L P. Advances in the treatment of overactive bladder. Guowai Yixue Miniao Xitong Fence, 2005, 25(1): 42–46.
5. JING S. Effect of pelvic floor muscle training combined with oxybutynin hydrochloride in relief of female patients with overactive bladder syndrome. Shiyong Linchuang Yiyao Zazhi, 2016, 20(10): 128–130.